Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$192.10M$192.10M+9.3% vs Q3 2024 Net Income-$45.12M-$45.12MN/M vs Q3 2024 EPS Diluted-$0.80-$0.80N/M vs Q3 2024 Operating Income-$60,231,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$61,793,000N/M Margins · derivedOperating margin-31.4%−54.6 pt vs Q3 2024
Net margin-23.5%−45.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end